Yi Lin - Concepedia

Author

Yi Lin

Also Known As

Buyske, Steven, Casey, Graham, Chen, Chu, Conghui Qu, Deelman, Ewa, Giovannucci, Edward L., Hutter, Carolyn M., Juha Peltonen, Lin Yi, Lin, Yi

Publications

37.9K

Citations

H-Index

235

Concepts

All Affiliations

Mayo Clinic in Arizona Mayo Clinic Mayo Clinic in Florida The University of Texas MD Anderson Cancer Center Moffitt Cancer Center

About

Yi Lin is an author at Mayo Clinic in Arizona specializing in medicine, immunology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	39	98	9.2K
2	Health Sciences	22	38	4.2K
3	Engineering	4	4	94
4	Natural Sciences	2	2	69
5	Business	1	1	18

Yi Lin

267

Publications

32.4K

Citations

H-Index

Page 1

	Year	Citations
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, New England Journal of Medicine	2017	5.7K
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma Nikhil C. Munshi, Larry D. Anderson, Nina Shah, New England Journal of Medicine	2021	2.3K
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaAxicabtagene CiloleucelMedicineImmunology	2018	2.2K
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma Noopur Raje, Jesús G. Berdeja, Yi Lin, New England Journal of Medicine	2019	1.7K
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani, The Lancet Hematological MalignancyCell TherapyImmunotherapyCiltacabtagene AutoleucelMedicine	2021	1.5K
Origins of circulating endothelial cells and endothelial outgrowth from blood Yi Lin, Daniel J. Weisdorf, Anna Solovey, Journal of Clinical Investigation	2000	1.5K
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Loretta J. Nastoupil, Michael D. Jain, Lei Feng, Journal of Clinical Oncology	2020	752
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study Bijal Shah, Armin Ghobadi, Olalekan O. Oluwole, The Lancet Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyHematology	2021	721
Circulating Activated Endothelial Cells in Sickle Cell Anemia Anna Solovey, Yi Lin, Paul Browne, New England Journal of Medicine	1997	637
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up Thomas G. Martin, Saad Z. Usmani, Jesús G. Berdeja, Journal of Clinical Oncology	2022	580

Page 1